Petrichor Healthcare Capital Management

What Petrichor Healthcare Capital Management does

Petrichor Healthcare Capital Management is a New York-based private investment firm founded in 2018 by Tadd Wessel alongside partners Patrick Lally and Michael Beecham, all previously of OrbiMed Advisors and Fortress Investment Group. The firm operates a dual-platform investment strategy focused exclusively on the healthcare and life sciences sector: Petrichor Capital Partners provides growth capital through customized convertible debt and equity structures to late-stage and commercial-stage biopharmaceutical, medical technology, diagnostics, and tech-enabled healthcare services companies, with typical investment sizes of $10 million to $50 million (expandable through limited partner co-investments); while Scion Life Sciences, an affiliated venture capital fund launched in February 2024 with $310 million in capital, focuses on founding and building exceptional biotechnology companies from inception through commercial maturity, deploying up to $60 million per portfolio company.

The firm generates revenue through standard private equity and venture capital economics, primarily management fees on committed capital and carried interest on realized gains, while adding value through active board participation (more than 60 board seats historically) and strategic advisory. To date, Petrichor's team has executed over 130 investments representing more than $6 billion of invested capital, including structured investments in Cryoport, ClearPoint Neuro, Fennec Pharmaceuticals, Tourmaline Bio, Aurion Biotech, Palvella Therapeutics, and many others across therapeutic, diagnostic, and healthcare services subsectors. Notable recent exits include Tourmaline Bio's agreement to be acquired by Novartis AG (September 2025), Lantheus Holdings' acquisition of Evergreen Theragnostics (April 2025, $250 million upfront), and Alcon's majority acquisition of Aurion Biotech (March 2025).

Petrichor's go-to-market is relationship-driven and highly specialized: the firm sources deals through direct engagement with management teams and boards, co-investor networks (Deerfield, KKR, Flying L Partners, PTC Therapeutics), and its portfolio-company referral base, and distributes capital and strategic support directly rather than through traditional channels. Limited partner relationships are anchored by institutional capital, with Archean Capital Partners serving as the anchor investor for the inaugural $410 million Petrichor Opportunities Fund I (November 2020). The firm maintains a small team (11-50) of scientific, medical, financial, and operational leaders, supplemented in 2026 by senior operating partners Don Hardison (former Exact Sciences CEO) and Paul Sekhri (former eGenesis CEO).

Name

Petrichor Healthcare Capital Management

Legal name

Petrichor Healthcare Capital Management

Website

https://petrichorcap.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Petrichor Healthcare Capital Management is a New York-based private healthcare investment firm operating a dual-platform strategy: Petrichor Capital Partners deploys structured growth capital to late-stage biopharma, medtech, diagnostics, and healthcare services companies, while affiliated Scion Life Sciences founds and builds early-stage biotechnology companies across global markets.

Ownership category

akta.pro rank

Product category

Healthcare Private Equity / Venture Capital Investment Management

NAICS

Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

• Healthcare private equity
• Growth capital investing
• Biopharmaceutical financing
• Medical technology investment
• Venture capital funds

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others, Infrastructure

Revenue model

1. Investment Returns: Petrichor generates returns through equity investments, convertible debt, and structured financing in healthcare companies. The firm participates in board representation and strategic advisory services to support portfolio company growth and eventual exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Petrichor Healthcare Capital Management is a private investment firm that provides customized growth capital to healthcare companies, deploying combined convertible debt and equity financing of $10 million to $50 million per transaction to late-stage and commercial-stage biopharmaceutical, medical technology, diagnostics, and tech-enabled services companies. Through its affiliated venture capital fund Scion Life Sciences, Petrichor also founds and builds biotechnology companies from inception through commercial maturity. Beyond capital, the firm provides strategic advisory and board-level support across more than 60 portfolio company board seats.

Product overview

Petrichor Healthcare Capital Management operates as a dual-platform investment firm with two core products: Petrichor Capital Partners provides growth capital through combined convertible debt/equity structures to late-stage and commercial-stage healthcare companies in biopharmaceuticals, medical technology, diagnostics, and tech-enabled services. Scion Life Sciences is a dedicated venture capital fund for founding and building exceptional biotech companies from pre-seed through commercial maturity, capable of deploying up to $60 million per portfolio company over its investment life. The platforms share operational infrastructure and team but serve distinct investment stages and strategies within the healthcare and life sciences ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• Scion Life Sciences: A venture capital fund dedicated to founding and building exceptional biotechnology companies that discover, develop and seek to commercialize clinically transformational or curative new medicines.

Products and services

• Petrichor Capital Partners Growth investment strategy providing combined convertible debt and equity capital of $10 million to $50 million per transaction to late-stage and commercial-stage healthcare companies across biopharmaceuticals, medical technology, diagnostics, and tech-enabled services, with the ability to commit larger amounts via limited partner co-investments. Includes strategic advisory and board representation alongside capital deployment, serving both public and private companies globally.
• Scion Life Sciences Venture capital fund dedicated to founding and building exceptional biotechnology companies that discover, develop, and seek to commercialize clinically transformational or curative new medicines, structured to support portfolio companies from pre-seed through IPO with long-term capital deployment of up to $60 million per company over its investment life.

Quantifiable outcome

• Over 130 investments representing more than $6 billion of invested capital
• +2 more outcomes

Named customers18 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Scion Life SciencescoreStrategic or Co-development Partner · 1 January 2018Scion Life Sciences is an affiliate of Petrichor, dedicated to founding and building exceptional biotechnology companies. Scion launched with $310 million in February 2024 and operates as a separate venture capital fund with shared leadership including Tadd Wessel.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• OrbiMed Advisors: Global healthcare-dedicated investment firm across venture, growth, and public equity. Petrichor's three founders (Wessel, Lally, Beecham) previously built OrbiMed's structured investment business together, making it the closest comparable on team DNA and healthcare focus.
• Apple Tree Partners: Biotech-focused venture firm that builds companies from inception through clinical milestones. Scion's founders (Samuel Hall, Aaron Kantoff, Andreas Loew) were partners at Apple Tree, making strategy, team, and company-formation model directly comparable.
• Deerfield Management: Healthcare-focused investment firm providing growth capital, venture, and structured financing across biopharma, medtech, and diagnostics. Deerfield co-invested alongside Petrichor in Aurion Biotech ($120M round) and represents the largest direct competitor in the structured healthcare growth space.
• Medicxi: European healthcare-focused venture firm that founds and develops therapeutic companies from inception. Aaron Kantoff (Scion co-founder) was a Venture Partner at Medicxi, and the firm shares Scion's biotech company-builder model.
• Atlas Venture: Biotech-focused early-stage venture firm that builds companies from inception through clinical development. Comparable to Scion's company-formation model and shares a similar New York/Cambridge-based biotech orientation.
• Versant Ventures: Healthcare-focused venture firm with company-formation model (Inception Sciences) similar to Scion. Operates across therapeutics, medtech, and digital health, providing direct comparable on strategy and team model.
• venBio Partners: Biotech-focused venture firm investing across company stages. Operates with a similar healthcare-only mandate and active board participation model, providing a close comparable on portfolio approach.

Broad incumbents

• Baker Bros. Advisors: Long-tenured biotech-focused public and private investment manager with multi-billion AUM. Operates across both public equities and private healthcare venture, providing a comparable healthcare-only mandate but at materially larger scale.
• RA Capital Management: Healthcare-focused crossover fund investing across public and private biopharma and medtech. RA Capital's late-stage growth equity activity competes directly with Petrichor Capital Partners for deal flow and LP capital.

Emerging players

• Pontifax Venture Capital: Healthcare-dedicated venture firm investing in therapeutics and medical technology across stages. Smaller AUM than Petrichor's combined platform but comparable in mandate and stage focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/petrichor-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Petrichor Healthcare Capital Management